Alvotech (NASDAQ:ALVO) Sees Strong Trading Volume – What’s Next?

Alvotech (NASDAQ:ALVO) saw strong trading volume on Friday . 1,260,668 shares changed hands during mid-day trading, an increase of 96% from the previous session’s volume of 641,961 shares.The stock last traded at $4.48 and had previously closed at $4.27.

Alvotech News Roundup

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Alvotech signed a licensing and commercialization agreement with Lotus Pharmaceutical covering proposed biosimilars AVT34, targeting Imfinzi (durvalumab), and AVT87, targeting Hemlibra (emicizumab), in the United States and selected Asian markets. The deal is valued at up to approximately $150 million and expands Alvotech’s potential commercial reach. Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical
• Positive Sentiment: The FDA accepted resubmitted applications for AVT05, a proposed Simponi biosimilar, AVT06, a proposed Eylea biosimilar, and partner Dr. Reddy’s AVT03, targeting Prolia/Xgeva. FDA decisions are expected in the fourth quarter of 2026, creating important approval and launch catalysts. Alvotech Announces Financial Results for the First Half of 2026
• Positive Sentiment: Alvotech said manufacturing returned to planned operating levels near the end of the second quarter after facility improvements constrained output. Management expects stronger product availability and commercial performance in the second half, supported by strong underlying demand in the U.S. and Europe.
• Positive Sentiment: The company projects 2026 revenue of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million. It also strengthened liquidity with approximately $165 million from an equity offering and private placement, plus a new $75 million term loan.
• Neutral Sentiment: Alvotech’s Reykjavik facility received a “Voluntary Action Indicated” classification following an FDA inspection, a favorable compliance outcome but not a product approval.
• Negative Sentiment: First-half adjusted revenue fell 30.8% to $211.9 million, while product and service revenue dropped 48.3%. Adjusted EBITDA declined to $46.9 million, and cash decreased to $142.8 million, highlighting execution and liquidity concerns.
• Negative Sentiment: Second-quarter adjusted loss was $0.11 per share, wider than the expected $0.05 loss, although quarterly revenue of $105.77 million exceeded estimates. The equity financing also creates potential shareholder dilution.

Analysts Set New Price Targets

ALVO has been the subject of several analyst reports. Evercore started coverage on Alvotech in a research note on Friday, August 14th. They issued an “outperform” rating for the company. Weiss Ratings lowered Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Finally, Wall Street Zen cut Alvotech from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Alvotech presently has a consensus rating of “Hold” and an average target price of $7.60.

Alvotech Stock Performance

The company has a market cap of $1.34 billion, a price-to-earnings ratio of -7.26 and a beta of 0.18. The stock’s fifty day simple moving average is $3.66 and its two-hundred day simple moving average is $3.75.

Alvotech (NASDAQ:ALVO) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The firm had revenue of $105.77 million for the quarter, compared to analysts’ expectations of $103.00 million. Alvotech had a negative net margin of 36.31% and a negative return on equity of 11.92%. Analysts predict that Alvotech will post 0.05 EPS for the current fiscal year.

Institutional Trading of Alvotech

A number of institutional investors have recently modified their holdings of ALVO. ProShare Advisors LLC lifted its holdings in shares of Alvotech by 24.0% during the 4th quarter. ProShare Advisors LLC now owns 13,826 shares of the company’s stock valued at $71,000 after acquiring an additional 2,675 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Alvotech by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company’s stock worth $78,000 after purchasing an additional 3,110 shares during the period. Magnetar Financial LLC acquired a new stake in Alvotech in the 3rd quarter valued at $86,000. Orion Porfolio Solutions LLC acquired a new stake in Alvotech in the 3rd quarter valued at $92,000. Finally, Stifel Financial Corp purchased a new position in Alvotech in the fourth quarter valued at about $108,000.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).